Back to list

In France, around 1.3 million people are affected by Age Related Macular Degeneration (ARMD), a particularly incapacitating eye condition which deprives the sufferer of his or her central vision. It therefore prevents the sufferer from reading, driving or watching television. It is the first cause of blindness in the over 50's. Early screening means that the progression of the disease can be slowed down.
The objective of the MAPI project is to compare two methods of measurement of the macular pigment with the aim of developing a protocol which would allow people at risk from ARMD to be identified in the early stages. Its implementation is based on a partnership between the 'Institut Pasteur de Lille', the ' CHRU de Lille' and 'Métrovision'.
Over the long term, this project would allow the Nord-Pas de Calais region to be equipped with state-of-the-art equipment that would enable people at risk from ARMD to be screened efficiently early on. Ophthalmologists' interest in macular pigment, its physiological function and its role in the prevention of ARMD has been on the increases since the start of the last decade. Therefore, measurement of macular pigment should soon become widely available. Clinical ophthalmologists would be able to assess the density of macular pigment in vivo, screen subjects presenting a low density of macular pigment and offer them suitable dietary advice and/or an antioxidantet supplement aimed at preventing ARMD.

This project, labelised by the AQUIMER Pole of Competitiveness on the 22nd April, 2010, is co-labelised with the ' Pôle Nutrition Santé Longévité'.


16 rue du Commandant Charcot
62200 Boulogne-sur-Mer F

Tel : 00 333 21 10 78 98

Fax : +33 3 21 30 33 22



Subscribe to newsletter